3613 — Beijing Tong Ren Tang Chinese Medicine Co Income Statement
0.000.00%
- HK$7.14bn
- HK$5.62bn
- HK$1.61bn
- 85
- 55
- 58
- 77
Annual income statement for Beijing Tong Ren Tang Chinese Medicine Co, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | HKAS | HKAS | HKAS | HKAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,315 | 1,556 | 1,731 | 1,525 | 1,612 |
Cost of Revenue | |||||
Gross Profit | 953 | 1,120 | 1,150 | 1,047 | 1,065 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 646 | 778 | 920 | 901 | 1,035 |
Operating Profit | 669 | 778 | 812 | 624 | 577 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | 686 | 778 | 826 | 688 | 630 |
Provision for Income Taxes | |||||
Net Income After Taxes | 568 | 652 | 691 | 591 | 529 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 542 | 608 | 646 | 540 | 500 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 542 | 608 | 646 | 540 | 500 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.647 | 0.726 | 0.771 | 0.643 | 0.598 |
Dividends per Share | |||||
Special Dividends per Share |